• HOME
• ABOUT
  • MANAGEMENT
  • BOARD OF DIRECTORS
  • SCIENTIFIC AND MEDICAL ADVISORY BOARD
  • ACADEMIC COLLABORATIONS
  • PARTNERSHIPS
• SCIENCE
  • TARGET
  • METABOLIC SYNDROME
  • TYPE 2 DIABETES
  • INSULIN SENSITIZERS
  • NEURODEGENERATION
• PIPELINE
  • MSDC-0160
  • MSDC-0602
  • MARKET
• NEWSROOM
  • NEWS RELEASES
  • IN THE NEWS
  • PUBLICATIONS
  • PRESENTATIONS
  • FACT SHEET
• CONTACT
  • LOCATION
  • CAREERS
  • MEDIA CONTACT

The leaders of Metabolic Solutions Development Company are frequently asked to speak on diabetes, insulin sensitizers and mitoglitazone. Supporting materials from select presentations are listed below.

EASD Presentation, Lisbon 2011
New Insulin Sensitizers Produce Differentiation of Brown-like Adipose Cells from a Subcutaneous Fat Depot and Increase Secretion of Adiponectin in vitro (PDF)

ADA Presentation, San Diego 2011
Enhancement of Brown Adipose Tissue Development in vivo by a Novel Insulin Sensitizer  (PDF)

ADA Poster, San Diego 2011
Novel Insulin Sensitizers Enhance Brown Adipose Cell Differentiation by Modulation of the Wnt Signaling Pathway (PDF)

IDF World Diabetes Congress Poster, Montreal 2009
A PPAR-sparing insulin sensitizer is effective in type 2 diabetic patients without causing weight gain (PDF)

MD Conference Express: Diabetes, EASD Highlights, September 2008, excerpt
Mitoglitazone and PPAR-sparing insulin sensitizers (PDF)

EASD Abstract, Rome 2008
PPAR-sparing insulin sensitizers; path for development and clinical evaluation (PDF)